Achieved development and regulatory milestone included accounts receivable.

No definition available.

Name:	arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable
Namespace Prefix:	arct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Additional financial support

+ References

No definition available.

+ Details

Name:	arct_AdditionalFinancialSupport
Namespace Prefix:	arct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Additional payments upon meeting certain clinical milestones.

+ References

No definition available.

+ Details

Name:	arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones
Namespace Prefix:	arct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Development and regulatory milestones achieved.

+ References

No definition available.

+ Details

Name:	arct_DevelopmentAndRegulatoryMilestonesAchieved
Namespace Prefix:	arct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Development milestones received advance payment.

+ References

No definition available.

+ Details

Name:	arct_DevelopmentMilestonesReceivedAdvancePayment
Namespace Prefix:	arct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Eligible to receive commercial milestone payment.

+ References

No definition available.

+ Details

Name:	arct_EligibleToReceiveCommercialMilestonePayment
Namespace Prefix:	arct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Eligible to Receive Development Milestone Payment

+ References

No definition available.

+ Details

Name:	arct_EligibleToReceiveDevelopmentMilestonePayment
Namespace Prefix:	arct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Grant revenue.

+ References

No definition available.

+ Details

Name:	arct_GrantRevenue
Namespace Prefix:	arct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Grant revenue outstanding.

+ References

No definition available.

+ Details

Name:	arct_GrantRevenueOutstanding
Namespace Prefix:	arct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payments.

+ References

No definition available.

+ Details

Name:	arct_MilestonePayments
Namespace Prefix:	arct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of net profits.

+ References

No definition available.

+ Details

Name:	arct_PercentageOfNetProfits
Namespace Prefix:	arct_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Reserved upfront payment.

+ References

No definition available.

+ Details

Name:	arct_ReservedUpfrontPayment
Namespace Prefix:	arct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue.

+ References

No definition available.

+ Details

Name:	arct_RevenueLineItems
Namespace Prefix:	arct_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payment received.

+ References

No definition available.

+ Details

Name:	arct_UpfrontPaymentReceived
Namespace Prefix:	arct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_CounterpartyNameAxis=arct_SeqirusIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=arct_Covid19VaccineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=arct_VinbiocareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=arct_ForeignCountriesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=arct_ResearchCollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=arct_ManufacturingAndSupplyOfArct154DrugProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=arct_VinbiocareAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=arct_CslCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=arct_PhaseIClinicalStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=arct_StudySupportAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContractWithCustomerDurationAxis=us-gaap_ShortTermContractWithCustomerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue (Details Textual) - USD ($)		1 Months Ended		3 Months Ended		12 Months Ended
Revenue (Details Textual) - USD ($)	Nov. 01, 2022	Feb. 28, 2023	Aug. 31, 2022	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2024
Revenue [Line Items]
Collaboration revenue						$ 152,310,000	$ 166,799,000	$ 205,999,000
Deferred revenue						32,118,000	87,325,000
Revenue recognized						(152,806,000)	62,600,000
Seqirus Inc [Member]
Revenue [Line Items]
Collaboration revenue						96,000,000
Upfront payment received						200,000,000
Seqirus Inc [Member] \| COVID-19 Vaccine [Member]
Revenue [Line Items]
Deferred revenue						5,100,000
Revenue recognized				$ 5,300,000
Vinbiocare [Member]
Revenue [Line Items]
Deferred revenue						0
Remaining performance obligation						0
BARDA [Member]
Revenue [Line Items]
Revenue recognized						13,900,000	9,100,000
Total grant revenue			$ 63,200,000
Grant revenue outstanding						40,000,000
Foreign Countries [Member]
Revenue [Line Items]
Collaboration revenue						138,400,000	154,900,000	$ 192,700,000
Research Collaboration And License Agreement [Member] \| Seqirus Inc [Member]
Revenue [Line Items]
Upfront payment received	$ 200,000,000
Research Collaboration And License Agreement [Member] \| Seqirus Inc [Member] \| COVID-19 Vaccine [Member]
Revenue [Line Items]
Net profits percentage	40.00%
Development milestones received advance payment							5,300,000			$ 5,100,000
Research Collaboration And License Agreement [Member] \| Seqirus Inc [Member] \| Manufacturing and Supply of ARCT-154 Drug Product [Member]
Revenue [Line Items]
Deferred revenue						0
Revenue recognized					$ 18,000,000
Development milestones received advance payment							23,600,000
Research Collaboration And License Agreement [Member] \| Maximum [Member] \| Seqirus Inc [Member]
Revenue [Line Items]
Eligible to receive development milestone payment	$ 1,300,000,000
Eligible to receive commercial milestone payment	$ 3,000,000,000
Vinbiocare Agreement [Member]
Revenue [Line Items]
Upfront payment received									$ 40,000,000
Reserved upfront payment						11,800,000
Additional financial support		$ 2,100,000
Vinbiocare Agreement [Member] \| Vinbiocare [Member]
Revenue [Line Items]
Deferred revenue							0
CSL Collaboration Agreement [Member]
Revenue [Line Items]
Deferred revenue						30,700,000	87,100,000
Development and regulatory milestones achieved						72,200,000
Achieved development and regulatory milestone included accounts receivable						0
CSL Collaboration Agreement [Member] \| Phase I Clinical Study [Member]
Revenue [Line Items]
Deferred revenue						3,100,000
Revenue recognized						12,000,000	2,400,000
Milestone payments							17,500,000
CSL Collaboration Agreement [Member] \| Maximum [Member] \| Phase I Clinical Study [Member]
Revenue [Line Items]
Additional payments upon meeting certain clinical milestones							$ 1,500,000
Study Support Agreement [Member] \| Vinbiocare [Member] \| Short-Term Contract with Customer [Member]
Revenue [Line Items]
Accrued liabilities paid upon occurrence of specified events						$ 2,400,000